Clinical trial
Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With…
NCT00412542 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00412542 |
|---|---|
| Title | Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas |
| Official title | A Phase II Trial of Combination Therapy With Thalidomide and CPT-11 in Patients With Recurrent Anaplastic Gliomas or Glioblastoma Multiforme |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Celgene Corporation Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Glioblastoma Multiforme, Glioma |
| Intervention type | Drug, Procedure |
| Interventions | Thalidomide, CPT-11, MRI Scan, Quantitative Sensory Tests (QST) |
| Enrollment | 78 |
| Start date | Oct 1, 2003 |
| Primary completion | Oct 1, 2009 |
| Completion | Oct 1, 2009 |
| First posted | Dec 18, 2006 |
| Last update posted | Feb 28, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: